drugset / Trial / NCT06371326
A Study of ZT002 Injection in Participants With Overweight or Obesity
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will comprise a randomized, double-blind, placebo-controlled, multiple-ascending-dose, safety, tolerability, and pharmacokinetics study of ZT002 in participants with Overweight or Obesity.
Timeline
- Start
- 2023-11-21
- Primary completion
- 2024-04-15
- Completion
- 2024-10-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZT002 | Peptide | — | Subcutaneous |